Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Non-Current Deffered Revenue: 2010-2024

Historic Non-Current Deffered Revenue for Lineage Cell Therapeutics (LCTX) over the last 14 years, with Dec 2024 value amounting to $14.4 million.

  • Lineage Cell Therapeutics' Non-Current Deffered Revenue fell 22.36% to $12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.5 million, marking a year-over-year decrease of 22.36%. This contributed to the annual value of $14.4 million for FY2024, which is 22.79% down from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Non-Current Deffered Revenue stood at $14.4 million for FY2024, which was down 22.79% from $18.7 million recorded in FY2023.
  • In the past 5 years, Lineage Cell Therapeutics' Non-Current Deffered Revenue registered a high of $32.5 million during FY2021, and its lowest value of $14.4 million during FY2024.
  • Moreover, its 3-year median value for Non-Current Deffered Revenue was $18.7 million (2023), whereas its average is $20.3 million.
  • Data for Lineage Cell Therapeutics' Non-Current Deffered Revenue shows a maximum YoY tumbled of 32.58% (in 2023) over the last 5 years.
  • Over the past 4 years, Lineage Cell Therapeutics' Non-Current Deffered Revenue (Yearly) stood at $32.5 million in 2021, then dropped by 14.57% to $27.7 million in 2022, then crashed by 32.58% to $18.7 million in 2023, then dropped by 22.79% to $14.4 million in 2024.